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Platelet-rich plasma (PRP) can be widely used in veterinary medicine in different
areas. Studies using PRP frequently use different methodologies making for difficult
comparison. The objective of this study was to evaluate the purity and platelet activation
of a PRP protocol. A total of 18 blood samples were drawn from six dogs, collected once
per week over a total of three weeks. Blood samples were centrifuged six times at 300g
for 5 min. Ultra-pure PRP (OP) was obtained by adding PRP a Optiprep 1.063g/mL
density barrier and centrifuged at 350g for 15 min. Mean platelet recovery from whole
blood was 62.90% in PRP and 45.24% in OP. PRP and OP showed high platelet purity;
blood cell contamination <0.01%. Flow cytometry for platelet activation markers was
consistent with minimal platelet activation. This study describes the optimization of PRP
protocol with high platelet purity, minimal platelet activation, high reliability and
reproducibility.
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INTRODUCTION
Background
Blood platelets are derived from proplatelet cylinders of megakaryocyte
cytoplasm present in hematopoietic organs, such as bone marrow. Platelets are cytoplasm
fragments with no nucleus measuring from 2 to 4 µm in diameter (Harvey, 2012). The
resting platelet structure is divided into three zones, each one with a particular function.
The peripheral zone includes the glycocalyx coat, cytoskeleton, and platelet membrane
and is responsible for platelet adhesion and aggregation. The sol-gel zone is formed
mainly by the canalicular and dense tubular systems and is responsible for platelet
contraction and microtubule system support. The organelle zone is formed by alpha
granules, dense granules, lysosomal granules, and glycogen granules and contains more
than 800 different proteins involved in the major platelet functions (White, 2004; Senzel
et al., 2009).
The major functions of platelets include preventing acute blood loss and inducing
healing of the vascular system and adjacent tissues after injury (Amable et al., 2013).
During vascular injury, collagen is exposed and by contact activates platelets. Once
activated, platelets release stored cytokines, growth factors, coagulation factors, and other
molecules that are responsible for amplifying platelet activation. These factors also have
a paracrine effect in different cell populations, including mesenchymal cells, osteoblasts,
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fibroblasts, and endothelial cells and can lead to cellular proliferation, migration, and
angiogenesis, all important for tissue regeneration (Bambace and Holmes, 2011; Amable
et al., 2013). Other less known functions include anti-inflammatory, antibiotic, and
analgesic effects (Drago et al., 2013; Mazzocca et al., 2013).
Platelet-rich plasma in the veterinary medical practice
Platelet-rich plasma (PRP) is a concentrate of platelets in a relatively small
volume of plasma that has been largely used in regenerative medicine. The clinical use of
PRP in small animals is relatively recent and, similarly to what happens in human
medicine, has shown beneficial results.
Previous studies applying PRP in cutaneous wounds of different sizes and depths
in dogs have demonstrated that PRP induces a faster wound closure rate, increased
collagen deposition, granulation tissue formation, and better vascularization (Alishahi et
al., 2014; Jee et al., 2016). Similar results were also observed in humans(Eppley et al.,
2004) and horses (DeRossi et al., 2009). Case reports administering PRP as part of the
treatment in multiple or large cutaneous lesions in dogs have suggested decreased healing
time and better overall response (Kim et al., 2009; Chung et al., 2015). However, in a few
cases, the healing of cutaneous surgical wounds and cutaneous regeneration in dogs is not
so clearly affected by the use of PRP, even up to 10 days after injury (Sardari et al., 2011;
Karayannopoulou et al., 2015). Contradictory results of the benefit of the adjuvant
therapy with PRP in wound healing have also been observed in other species, such as in
horses (Monteiro et al., 2009).
Studies on reparative orthopedic surgery, focusing on musculoskeletal disorders
(e.g., osteoarthritis and meniscal healing), showed decreased pain and increased articular
2

function in dogs and horses receiving serial intra-articular PRP injections (Cook et al.,
2016; Girolamo et al., 2016 Bosch et al., 2011; Torricelli et al., 2011). In humans, the use
of PRP to treat acute and chronic injuries of bone and cartilage is well established
(Girolamo et al., 2016; Meheux et al., 2016; Riboh et al., 2016). Dehghan et al. (2015)
performed callus distraction after osteotomy in 10 dogs and used two different
treatments, application of PRP only and application of PRP associated with bone marrow
mesenchymal stem cells (BM-MSC). By radiographic and CT scan evaluations, they
observed higher osteogenesis rate and bone healing rate in dogs treated with both PRP
and BM-MSC, suggesting a paracrine effect of platelets on the proliferation of
mesenchymal stem cells. Similar results were also seen in rabbits (Jiang et al., 2012),
sheep (Hernandez-Fernandez et al., 2013Niemeyer et al., 2010), and mini-pigs (Hakimi et
al., 2010).
In dogs, the use of PRP caused faster mucosal healing and pulp revascularization
after treatment of injured tissue with PRP injections (Carlson and Roach, 2002; Tobita et
al., 2013). Simsek et al.,( 2012) found that PRP associated with mesenchymal stem cell
(but not PRP alone) lead to faster recovery from odontological implant surgery,
suggesting that in some cases the association of stem cells with PRP may be required for
better results.
Inconsistent results of the benefits of treatment with PRP are reported in human
medicine (Battaglia et al., 2013; Filardo and Kon, 2015) and in veterinary medicine
(Jensen et al., 2005). However, when comparing the numbers of published scientific
publications, it appears that there are fewer studies that found no benefits when using
PRP on reparative surgery than those with positive results. Part of this tendency may be
3

due to the fact that it is harder to have a manuscript with negative results accepted for
publication.
PRP in research
Many studies have suggested that platelets contribute to cancer progression and
metastasis by amplifying cancer-related coagulation, shrouding tumor cells and shielding
them from the immune system, and increasing intravasation of cancer cells (Bambace and
Holmes, 2011; Labelle et al., 2011). Evidence of the relationship between cancer cells
and platelets include the fact that thrombocytosis, thrombotic events, and/or increased
coagulation parameters are frequently associated with poor prognosis and high metastatic
rate (Gay and Felding-Habermann, 2011). For example, murine models of cancer with
impaired platelet function had shown a decreased metastatic rate (Camerer et al., 2004).
Also, platelets are able to take up cytokines and growth factors produced by cancer cells
and release them upon activation in metastatic sites, helping tumor metastasis (Kerr et al.,
2010). More specifically, there appears to be a positive correlation between the
concentration of angiogenic markers within platelets and increased aggressiveness in
osteosarcoma and mammary tumors in dogs (Selvarajah and Kirpensteijn, 2010).
In cancer research, PRP has been used to verify interactions between platelets and
cancer cells. But, despite the clear interaction between platelets and cancer cells, the
specific pathways and the difference between species are still largely unknown. Platelets
have also been used in the evaluation of cancer prognosis. A study has shown that, in
humans, an increased lymphocyte to platelet ratio is associated with a slower cancer
progression and decreased numbers of metastases in vivo (Zhang et al., 2016). These
4

findings were observed in different types of cancer, including breast cancer (Koh et al.,
2015) and gastric cancer (Aliustaoglu et al., 2010).
Since platelets can secret pro- and anti-inflammatory cytokines and uptake and
release regulatory plasma proteins, they have also been used to study the pathophysiology
of several diseases including cardiovascular and infectious diseases. Recently, new
aspects of the participation of platelets in the immune system have been described,
including the production and secretion of IL-1β and inflammasome assembly (Hottz et
al., 2015). Previous studies investigating the link between platelets and the immune
system have used malaria (Aggrey et al., 2013), dengue (Suharti et al., 2002; Bozza et
al., 2008), toxoplasmosis (Chumpitazi et al., 1998) and different gram-negative bacterias
(Yang et al., 2013) to activate platelets and then used proteome, transcriptome, and/or
specific secreted cytokines analysis to verify the role of platelets during the progression
of the disease. These studies suggest that initial activation of platelets during the disease
can be protective inducing an immune response, however, chronic platelet activation is
associated with vasculopathy, cardiovascular damage, and even shock (Aggrey et al.,
2013; Hottz et al., 2015).
Different protocols, different results
After all, despite some well-established advantages of the use of PRP in animal
and human medical practice, there are few studies with conflicting results. One of the
possible causes is the use of different protocols to obtain PRP without standardization of
platelet concentration, purity, and activation. Unfortunately, the variability of leukocyte
contamination, and platelet concentration and activation in PRP, and the different
5

volumes used in different studies make any effort to interpret the findings nearly
impossible (Ehrenfest et al., 2009).
PRP is a generic term, originally used in transfusion medicine, that is used for
many types of platelet-plasma products (Araki et al., 2012). The techniques to produce
PRP have some common steps: (1) blood is collected with anticoagulant and a first
centrifugation is performed to separate the blood into three main layers, including red
blood cell (RBC), buffy coat (platelets and leukocytes layer), and acellular plasma or
platelet-poor plasma (PPP) (Figure 1); (2) then platelets are collected from the peri-buffy
coat area. Those two steps vary greatly among protocols, but in general, all protocols
discard RBC and PPP and concentrate platelets.
Due to the recent increased demand for platelet-related research, a classification
of platelet concentrates has been suggested (Ehrenfest et al., 2009). This classification is
based on fibrin density and leukocyte content, and hopefully, it will increase the degree
of standardization of the procedures. It has been suggested that pure PRP (P-PRP), also
called leukocyte-poor PRP, does not contain a significant amount of leukocytes
(Ehrenfest et al., 2009; Riboh et al., 2016) and leukocyte-rich PRP (L-PRP or P-LRP)
would have higher concentrations of leukocytes. However, specific concentration levels
of leukocyte used to differentiate P-PRP and L-PRP were not stipulated. While some
studies classify P-PRP, as PRPs containing close to 0% leukocyte (Ehrenfest et al., 2009),
other studies classified P-PRP as a PRP having any WBC concentration lower than the
one in the blood used to obtain the PRP (Riboh et al., 2016). The other classification
includes: (1) platelet-rich fibrin (PRF), which can have leukocyte (L-PRF) or not (P-PRF)
and is characterized by the presence of fibrin; (2) activated form of PRP, a PRP gel
6

characterized by low-density fibrin that can also have leukocyte (L-PRP gel) or not (PPRP gel). Thus, platelet concentrates can be classified into four main groups (P-PRP, LPRP, PRP gel, and PRF). This classification is important once many commercial kits are
available and offer different final products (Ehrenfest et al., 2009).
Studies involving the optimization of protocols to obtain P-PRP have tested
different centrifugation speed, time, and temperature and frequently used only two
centrifugation steps. In humans, best platelet recovery was obtained with a relative
centrifuge force (RCF) between 200-300g and times ranging from 5 to 12 minutes , while
temperature seemed to have minimal influence on platelet retrieval (Amable et al., 2013)(
Araki et al. (2012)). Amable et al. (2013) obtained up to 69.5% platelet recovery from
whole blood (WB) with less than 0.3% of RBC and leukocyte contamination using a total
of 4.5ml of WB, while Araki et al. (2012) obtained more than 80% of platelet recovery
with 4.1-5.8% leukocyte contamination using a total of 40-72 mL of WB.
Efforts to standardize a P-PRP protocol specific for dogs have been made,
however, most routine PRP protocols were designed based on human protocols. The first
described PRP protocol for dogs using two-step centrifugation used
ethylenediaminetetraacetic acid (EDTA) as anticoagulant and obtained a final
concentration of 1,884,000 platelets/µL with 64,200 WBC/µL, resulting in one leukocyte
for every 29 platelets (Jensen et al., 2004). Silva et al. (2011) performed a protocol using
the anticoagulant acid citrate dextrose (ACD) and obtained a final concentration of
515,000 platelets/µL with 6,900 WBC/µL. Other studies using the anticoagulant sodium
citrate and comparing different RCF values obtained from 4x105 to 1.3x106 platelets/µL
(Choi et al., 2005; Ferraz et al., 2007). Unfortunately, without any characterization of
7

leukocyte or erythrocyte contamination, it was not clear that these methods were
successful.
Another recent study carried out in our laboratory, obtained P-PRP by using a
protocol other than two-step centrifugation. This protocol included a single centrifugation
step of blood collected in EDTA tubes using an optimized density gradient technique to
better separate RBC, buffy coat, and PPP. The result was a final platelet recovery of
51.56% with 99.99% purity (Trichler et al., 2013).
It is important to point out that the type of anticoagulant used might interfere with
platelet activation and concentration. The main available anticoagulants include heparin
sodium, sodium citrate, ACD, EDTA, and citrate-theophylline-adenosine-dipyridamole
(CTAD). Several studies have shown that the use of EDTA as an anticoagulant for the
PRP protocols may cause functional, structural, and biochemical alterations in platelets
(White and Escolar, 2000; Wilkerson and Shuman, 2001; Silva et al., 2011). Neufeld et
al. (1999) compared CTAD and sodium citrate and showed higher platelet activation and
aggregation when sodium citrate was used, suggesting that sodium citrate is not the best
choice for functional platelet assays. On the other hand, Lei et al. (2009) tested the effects
of different anticoagulants on the quality and efficacy of PRP and showed that ACD
keeps the best integrity of platelet structure over time preventing spontaneous activation.
ACD is the anticoagulant of choice in blood banks, primarily because it maintains platelet
viability for up to 6 hours. This longer platelet viability might be explained by the
presence of glucose associated with low citrate concentration (1.32%). The low citrate
concentration helps to keep the pH from falling and the glucose helps platelet metabolism
during in vitro storage keeping their viability (Holme, 1992; Lei et al., 2009).
8

Platelet activation analysis by Flow Cytometry
Platelet concentration and activation status are important factors for PRP. It is
expected that an adequate PRP contains at least 106 platelets/µL with low activation
(Marx, 2001; Amable et al., 2013). Once activated, platelets release a wide range of
growth factors, cytokines, and chemokines that are lost during PRP preparation and could
be essential for therapeutic and research applications (Amable et al., 2013). For this
reason, several studies aiming to optimize PRP preparation have tested different ways to
analyze platelet activation (Araki et al., 2012; Amable et al., 2013; Trichler et al., 2013).
In dogs, flow cytometric analysis to detect platelet activation was first developed
to evaluate dogs with suspected thromboembolic disease, allowing identification of
prothrombotic state and consequently early medical intervention to prevent
thromboembolic cases (Moritz et al., 2003). Flow cytometry assesses canine platelet
activation by measuring P-selectin expression, the presence of platelet aggregates and/or
platelet microparticles, and expression of phosphatidylserine in the outer cytoplasmic
membrane (Wills et al., 2006). Platelet aggregates and microparticles can be identified by
a forward-scatter plot (Figure 2) with flow cytometry and confirmed by specific platelet
markers (e.g. CD61).
P-selectin, also known as CD62P, is an inflammatory mediator stored in the αgranule membrane of platelets and in Weibel-Palade bodies in endothelial cells. CD62P
is expressed to the platelet surface during activation and degranulation by fusion of the αgranules membrane with the cytoplasmic membrane. The detection of P-selectin is
performed by using a conjugated anti-CD62P antibody. It is commonly used as a marker
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for platelet activation in humans (Koksch et al., 2001) and has been also studied in
horses (Segura et al., 2006) and baboons (Michelson et al., 1996).
Upon platelet activation, phosphatidylserine flips out from the inner leaflet of the
cytoplasmic membrane to the outer surface of the cytoplasmic membrane adding negative
charges (Brooks et al., 2002) and creating nucleation sites for coagulation. Detection of
phosphatidylserine can be done using a conjugated Annexin V, a phospholipid-binding
protein with high affinity for phosphatidylserine (Thiagarajan and Tait, 1990).
Phosphatidylserine is as commonly used as P-selectin, it is well-established, and it has
been used for the diagnosis of bleeding disorders in dogs (Brooks et al., 2002) and cell
death by apoptosis.
Objective
The objective of the present study was to establish and optimize a method for PRP
preparation in dogs. The final goal was to obtain a reliable and practical PRP protocol
focusing on high platelet recovery, purity, and low platelet activation.

Figure 1.1

Gradient cellular concentration after whole blood centrifugation.
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Figure 1.2

Forward and side-angle light scatter plots showing normal platelets, platelet
aggregates, and platelets microparticles.
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Figure 1.3

Before and after centrifugation of blood using Optiprep 1.063 density
barrier.
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MATERIALS AND METHODS
Animal care and use
All procedures were approved by the Mississippi State University Institutional
Animal Care and Use Committee under the approval number #15-103 and were in
compliance with the requirements at a facility accredited by the American Association for
Accreditation of Laboratory Care.
Sample collection
Six healthy female intact Walker hound dogs were used in this study. The dogs
were not in estrus throughout the experiment or exposed to any medications or vaccines
for at least two months before starting this study. Whole blood samples were collected by
jugular venipuncture with a 20-gauge needle directly into a glass vacutainer tube
containing 1.5 mL of ACD and approximately 8.5 mL of blood. ACD was composed by
0.48% (w/v) citric acid, 1.32% (w/v) sodium citrate and 1.47% (w/v) glucose. Each dog
was collected once a week during three consecutive weeks to analyze the reproducibility
of the method. All samples were processed within an hour after collection.
Hematological Analysis
Total blood cell count was determined in whole blood and after each
centrifugation. The blood cell counts were performed manually with a hemocytometer
13

(Hausser Scientific Co, Harsham, PA 19044) using standard phosphate-buffered saline
(PBS) to dilute the samples when necessary. Blood smears were performed to analyze
cellular morphology, the presence of activated platelets, and platelet aggregates. Whole
blood samples presenting visible fibrin formation or platelet aggregates were excluded.
PRP preparation
After blood collection and hematological analysis, whole blood was centrifuged at
300  g for 5 minutes at 12°C in a swinging bucket rotor with the brake turned off
(Eppendorf® Centrifuge 5804R). After centrifugation, samples were divided into three
visible layers (i.e. RBC, buffy coat, and PPP). The entire opaque platelet fraction between
the dense buffy coat (composed mainly by leukocytes) and the clear PPP layer was
collected and the fraction, called PRP-1, was transferred to a new plastic tube. Without
homogenization, the remaining blood sample was centrifuged for five more times and
five subsequent fractions PRP-2, PRP-3, PRP-4, PRP-5 and PRP-6 were collected as
described for PRP-1. Total platelet count was assessed in each PRP fraction before
combining all fractions (pooled PRP) for further procedures. Summary of procedures are
detailed in Figure 2.1.
Low erythrocytes PRP preparation
Approximately 3 mL of the pooled PRP was carefully layered over 5 mL of
1.063g/ mL density barrier (OptiPrepTM, Sigma-Aldrich®, St. Louis, MO, USA). The
sample was centrifuged at 350  g for 15 minutes at 20°C. Approximately 1-2 mL of the
platelet layer, localized close to the 4.5 mL mark of the tube, was collected and
transferred to a new plastic tube labeled PRP-Opt (Figure 2.1).
14

Flow Cytometry Analysis
A total of 12 samples, two samples from each dog (pooled PRP and PRP-Opt)
were used to evaluate the platelet activation status. The analysis was performed using the
FACScalibur flow cytometer and the Cell Quest Pro Software (BD Biosciences, San Jose,
CA, USA). Approximately 1 x 107 platelets were spun down and incubated either with
FITC-labelled Annexin V (BD Biosciences) or RPE-labelled mouse anti-human CD62P
(AbD Serotec) according to the manufacturer’s protocol. After incubation, samples were
washed and resuspended in PBS for analysis. As a positive control, platelets were
activated with thrombin (Chrono-log©, Havertown, PA 19083, ref #386) and collagen
(Chrono-log©, Havertown, PA 19083, ref #385) following the manufacturer’s protocol.
As negative controls, isotype-matched control for P-selectin (Mouse IgG1 Negative
Control RPE, MCA928A405, BIO-RAD) was used and annexin-binding buffer for
Annexin V. Platelets were displayed on log forward-angle versus log side-angle light
scatter plots. The platelets were gated and 10,000 events were recorded for each labeling.
The expression of those markers on platelets was quantified using the percentage of
positive events. The presence of potential microparticles and platelet aggregates was
recorded.
Statistical Analysis
Results were expressed as mean ± standard deviation. Statistical significance was
assessed by single-factor analysis of variance (ANOVA) in conjunction with a multiple
comparison test (i.e., Tukey’s test) to test the differences among the PRP samples. P <
0.005 was considered statistically significant.
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Figure 2.1

Materials and methods.
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Figure 2.1 (continued)
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RESULTS AND DISCUSSION
The goal of the present study was to optimize a PRP protocol to increase platelet
recovery and reduce other blood cell contamination. The reasoning for the use of multiple
centrifugation steps was that it would allow the recovery of the highest amount of the
platelet layer at each centrifugation without collecting the buffy coat (leukocytes) or the
PPP layer. It also could avoid the loss of all platelets from a sample if platelet activation
was to happen during the later stages of the protocol. This protocol used a fixed RCF, 300
 g, which was shown to give the best centrifugation results from other studies (Silva et
al., 2011; Araki et al., 2012; Amable et al., 2013).
First centrifugation step
Most of the PRP protocols include a first centrifugation step in which the plasma
layer above the buffy coat is collected and separated into a different tube. Then, the
whole plasma is centrifuged again at a higher RCF so that platelets can form a
concentrated pellet. In our experience using one step with high RCF is usually associated
with high platelet recovery but and increases the chance of platelet activation. Also, the
use of a low RCF (to avoid activation) with single centrifugation frequently cause loss of
platelets due to entrapment within the RBC layer.
The first centrifugation step resulted in a mean total concentration of 1.85x108
platelets (minimum of 1.91x107 platelets and maximum of 4.17x108 platelets) (Table 2.1).
18

The mean WBC contamination concentration in our PRP-1 was 733 cells/µL, lower than
any other canine PRP techniques described. In most of these other studies, optimization
of the PRP protocol was not the objective, as they were testing the benefits of PRP use in
small animals clinical settings. The lack of information related to the PRP volume and
total platelet recovery from all reviewed references precludes a more detailed comparison
between our results and theirs.
From second to the final centrifugation step
The combination of all centrifugation steps (PRP1 to PRP6) allowed a final
platelet recovery of 66.45% ± 32.15%. RBC contamination ranged from 0.14 to 9.06 cells
for every 104 platelets counted, while WBC ranged from 0.54 to 4.04 cells for every 109
platelets.
A significant increase in the mean total recovered platelet from the first to second
and third centrifugation step was observed. PRP-2 and PRP-3 had a significantly higher
(p<0.005) mean total platelet recovery than any other steps (Figure 3.2). No significant
difference in mean platelet recovery was observed between PRP-2 and PRP-3, or
between PRP-4, PRP-5, and PRP-6. However, a pattern of steady decrease in the number
of retrieved platelets was observed among sequential steps (Figure 3.1).
There was a significant variation of platelet recovery among different dogs
(p=0.0045). Table 2.2 shows the mean platelet recovery from individual dogs at each
centrifugation step.
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Table 3.1

Mean volume and platelet recovery after each centrifugation.

Mean
Blood
PRP-1
PRP-2
PRP-3
PRP-4
PRP-5
PRP-6
Values
Volume
8,500
517.4
819.5
745.8
516.3
429
402
(µL)
Platelets 2.17E+09 1.85E+08 4.70E+08 3.77E+08 2.22E+08 1.65E+08 1.10E+08

Table 3.2
Animal

Mean platelet recovery in each dog after each centrifugation.
Blood

PRP-1

PRP-2

PRP-3

PRP-4

PRP-5

PRP-6

1

2.35E+09

7.20E+07

2.79E+08

3.16E+08

3.23E+08

3.32E+08

1.92E+08

2

1.78E+09

1.90E+07

1.46E+08

1.31E+08

1.61E+08

1.07E+08

1.58E+08

3

2.06E+09

2.67E+08

6.66E+08

5.27E+08

2.51E+08

1.10E+08

7.60E+07

4

2.05E+09

1.61E+08

4.29E+08

4.75E+08

2.15E+08

2.09E+08

7.50E+07

5

2.11E+09

4.17E+08

8.42E+08

4.57E+08

9.80E+07

3.20E+07

1.80E+07

6

2.67E+09

1.75E+08

4.57E+08

3.58E+08

2.84E+08

2.02E+08

1.41E+08

Mean

2.17E+09

1.85E+08

4.70E+08

3.77E+08

2.22E+08

1.65E+08

1.10E+08

Ultra-pure PRP procedure
After centrifugation of 3 mL of PRP with 5 mL of Optiprep 1.063g/mL, the final
platelet recovery from blood was 46.01%± 24.78%. RBC decreased from 9,350 RBC /
107 platelets to 0.0164 RBC / 107 platelets and WBC varied from 0.0126 WBC / 107
platelets to 0.0158 WBC / 107 platelets. It is possible that there was a decrease in
leukocytes contamination that was masked by the sensitivity of the test used to count
leukocytes. The minimum detection limit of leukocytes using hemocytometer and manual
counting is 1.1 WBC/uL and several counts were already at this level at the PRP total
step. The average number of total platelets harvested was 1.03x109 ± 0.49x109 platelets.
Blood components have different densities. Erythrocytes are the densest cells with
a specific gravity of approximately 1.095 kg/m3, followed by WBC, which specific
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gravity ranges from 1.063 to 1.085 kg/m3, and platelets with a specific gravity of
approximately 1.032 kg/m3. The plasma specific gravity varies from 1.025 to 1.029
kg/m3. Because of these characteristics, centrifugation is able to separate different blood
components in separate layers. Contamination of PRP usually occurs in part due to the
slightly overlapping specific gravities among other blood components (Araki et al., 2012)
and in part due to cell-cell interactions. The use of density gradient centrifugation has
shown to improve purity and quality of PRP by improving separation of its different
layers after centrifugation (Birschmann et al., 2008; Trichler et al., 2013).
Tables 2.3 and 2.4 show the mean percentage of platelet recovered from the blood
samples at the end of the six centrifugation steps (polled PRP) and after Optiprep (PRPOpt) centrifugation, along with the number of RBC and WBC counted for every 107
platelets. Overall the use of Optiprep did not cause statistically significant loss of
platelets. Interestingly, it was possible to observe that the ‘dog 2’ had the lowest
percentage of platelet recovery after Optiprep centrifugation 31.57% (Table 2.4), and this
finding was observed in all the three repetitions for this animal, but not for the others.
This suggests an individual factor, such as hydration status, high hematocrit, lipemia,
circadian rhythms in platelet numbers (Boswell et al., 2012; Smith et al., 2012), or higher
overlap of specific gravities.
An association between hematocrit, platelet aggregation, and platelet recovery has
been described in humans (Kelton et al., 1980; Boswell et al., 2012). Platelet aggregates
have higher sedimentation rate than the individualized platelets, and after centrifugation,
aggregates tend to stay closer to the RBC layer (Rinnovati et al., 2016).
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Kelton et al. (1980) showed that women have lower hematocrit and higher platelet
aggregation when using citrate, 9v:1v proportion, to collect the blood. Adjusting of the
citrate concentration to the hematocrit values of individual persons decreased the
differences. No evident difference in platelet concentration between female and male
dogs was found (Bauer et al., 2009). However, Smith et al. (2012) showed the association
between hematocrit and platelet recovery in PRP from dogs. They evaluated coagulation
parameters in 127 dogs and observed that RBC acts as functional diluent of blood, so
high hematocrit limits plasma volume, reducing recovery of platelets. The same negative
association between hematocrit and platelet yield was also observed in rabbits (Andrade
et al., 2008). In horses, hydration status appears to interfere with platelet retrieval
(Rinnovati et al., 2016). It is expected that dehydrated animals, with higher hematocrit
and decreased plasma volume, will decrease platelets recovery for the same reasons seen
in animals presenting higher hematocrit without dehydration. We did not evaluate
hematocrit at the days of the experiment, but during routine evaluations ‘dog 2’ often
present a hematocrit that was higher (up to 8%) than the other animals.
Table 3.3

Mean percentage of platelets recovered in the pooled PRP.

Animal

Platelet recovery
WBC/ 107
RBC/ 107 platelets
(%)
platelets
54.67%
0.0085
140
1
42.57%
0.0404
8,790
2
74.16%
0.0072
150
3
73.75%
0.0072
7,810
4
95.87%
0.0054
3,130
5
49.66%
0.0083
9,060
6
Mean
66.45%
0.0126
9,350
Mean percentage of platelets recovered in the pooled PRP in each dog and numbers of
white blood cells (WBC) and red blood cells (RBC) counted for every 107 platelets.
Platelet recovery was compared to the total number of platelets counted in the blood.
22

Table 3.4

Mean percentage of platelets recovered in the PRP-Opt.

Animal

% Platelet recovery
% Platelet recovery
WBC/ 107
RBC/ 107
from total blood
from PRP
platelets
platelets
40.87%
74.29%
0.0119
0.0119
1
31.57%
59.45%
0.0221
0.0221
2
66.87%
91.06%
0.0080
0.0104
3
41.19%
57.07%
0.0126
0.0126
4
70.20%
69.73%
0.0077
0.0077
5
41.34%
86.25%
0.0097
0.0097
6
Mean
46.01%
72.04%
0.0158
0.0164
Mean percentage of platelets recovered in the PRP-Opt in each dog and numbers of white
blood cells (WBC) and red blood cells (RBC) counted for every 107 platelets. Platelet
recovery was compared to the total number of platelets counted in blood and poll.
Method Reproducibility
The experiment was carried out three times for each dog in three different weeks.
Within the same dog, there was no evident differences in platelet recovery between
collections (p=0.6114) or between centrifugations (p=0.2675), what suggests high
reproducibility of the protocol.
Flow Cytometric Analysis
A significant difference (p=0.0032) in the percentage of Annexin V binding and
platelet aggregates were observed between thrombin-activated PRP and Optiprep and
between collagen-activated PRP and Optiprep, showing that platelet function was
maintained during the protocol. Figure 3.3 indicates that PRP maintained a low mean cell
fluorescence percentage (3.29 % ± 1.04 %) and that there was no significant difference in
fluorescence when compared to Optiprep samples (3.48 % ± 1.74 %). These results
suggest that no significant activation occurred across multiple centrifugation steps or
Optiprep procedure. The highest platelet activation rate in our positive controls was
observed using collagen and PRP (33.53 % ± 8.51 %). Despite the low platelet activation
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percentage using the standardized protocol, individual variations were observed. Possible
causes include handling, centrifugation, and individual physiological factors. Our results
were similar than those observed in other studies involving dogs (Brooks et al., 2002;
Wills et al., 2006). Wills et al. (2006) observed higher variability in their results, in which
non-activated samples expressed 1.1-7.3% mean cell fluorescence, while activated
samples ranged from 7 to 47.3%. These variabilities led the authors to conclude that
Annexin V should not be the first option for platelet activation studies and clinical
settings (Wills et al., 2006). However, in this study, little overlap was detected between
PRP samples and controls, suggesting that it was a good marker for platelet activation.
Differently from Annexin V, P-selectin labeling did not show a significant
difference (p=0.083) in the percentage of mean platelet fluorescence between pooled PRP
and Optiprep, thrombin-activated PRP and Optiprep, and collagen-activated PRP and
Optiprep (Figure 3.4). Our positive controls showed the lower mean percentage of cell
fluorescence when compared with other studies using dogs, in which the positive control
ranged from approximately 18% to 30% fluorescence (Moritz et al., 2003,2005; Trichler
et al., 2013). In this study, our activated polled PRP expressed 11.98% fluorescence for
thrombin and 7.61% for collagen and the activated PRP-Opt expressed 5.01%
fluorescence for collagen and 7.97% for thrombin. Similarly, Wills et al. (2006) showed
fluorescence range from 0.4 to 6.85% in activated samples, suggesting that low intensity
labeling with p-selectin is not uncommon.
Alpha-thrombin (Chrono-log©, Havertown, PA 19083, ref #386) was used to
activate platelets, leading to a clot formation. Despite the attempt to mechanically break
the clot, there was a clear decrease in the numbers of platelets when we used thrombin to
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activate platelets. Figure 3.5 show the decreased in platelet numbers (gated population)
on scatter plot in comparison with a non-activated sample. There is also an increase in
debris, possibly in part, due to an increased in the number of microparticles. The loss of
platelets by entrapment in fibrin clot could have been avoided by the use of gammathrombin. Gamma-thrombin is a form of thrombin that activates platelets but has a weak
effect in fibrin formation.

Figure 3.1

Mean platelet recovery.

Mean platelet recovery after each centrifugation (PRP-1 – PRP-6), polled PRP, and after
centrifugation on a 1.063 g/ml iodixanol density barrier (PRP-Opt).
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Figure 3.2

Multiple comparison test using mean total platelet recovery and t-grouping.

Multiple comparison test (ANOVA, Turkey’s test, α=0.05) based on each mean total
platelet across different centrifugation steps (PRP1 to PRP6). Means with same letter are
not significant different.
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(A)

(B)
Figure 3.3

Platelet activation status using Annexin V.

Platelet activation status was evaluated using Annexin V. (A) Pooled PRP and PRP-Opt.
(B) Pooled PRP + collagen, Pooled PRP + thrombin, PRP-Opt + collagen, and PRP-Opt
+ thrombin (collagen and thrombin were used to activate platelets and served as positive
controls in the flow cytometry protocol).
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(A)

(B)
Figure 3.4

Platelet activation status using P-selectin.

Platelet activation status was evaluated using P-selectin. (A) Polled PRP and PRP-Opt.
(B) Pooled PRP + collagen, Pooled PRP + thrombin, PRP-Opt + collagen, and PRP-Opt
+ thrombin (collagen and thrombin were used to activate platelets and served as positive
controls in the flow cytometry protocol).
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Figure 3.5

Platelet populations identified by flow cytometry.

Platelet populations identified by flow cytometric display in a forward-angle versus sideangle light scatter plots. On the left, non-activated Thrombin sample – Optiprep PRP. On
the right, PRP activated sample by Thrombin.
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CONCLUSION
The first step of the objective of this study was to develop and optimize a
procedure for harvesting PRP from dogs. An average of 1.40x 109 ± 0.63x 109 platelets
was recovered from 8.5 mL of WB with minor WBC and RBC contamination. The
second step was to generate an ultra-pure PRP, that was obtained using Optiprep 1.063.
The ultra-pure PRP generated had an average of 0.0164 RBC / 107 platelets and 0.0158
WBC / 107 platelets. The ultra-low numbers of RBC and WBC contamination are
desirable for several applications, including proteomics and transcriptomics analysis. It
was evident by Annexin V labeling that the harvested platelets were functional and that
activation due to the protocol was minimal to nonexistent. Thus, loss of platelet content
due to degranulation was unlikely.
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in horses. Acta Cirúrgica Brasileira 24:276-281.
Drago, L., M. Bortolin, C. Vassena, S. Taschieri, and M. Del Fabbro. 2013.
Antimicrobial activity of pure platelet-rich plasma against microorganisms
isolated from oral cavity. BMC Microbiology 13:47.
Ehrenfest, D.M.D., L. Rasmusson, and T. Albrektsson. 2009. Classification of platelet
concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and plateletrich fibrin (L-PRF). Trends in Biotechnology 27:158-167.
Eppley, B.L., J.E. Woodell, and J. Higgins. 2004. Platelet quantification and growth
factor analysis from platelet-rich plasma: implications for wound healing. Plastic
and Reconstructive Surgery 114:1502-1508.
Everts, P.A., A. van Zundert, J.P. Schonberger, R.J. Devilee, and J.T. Knape. 2008. What
do we use: platelet-rich plasma or platelet-leukocyte gel? Journal of Biomedical
Materials Research. Part A 85:1135-1136.
Ferraz, V.C.M., C.R.A. Ferrigno, and A. Schmaedecke. 2007. Platelet concentration of
plateletrich plasma from dogs, obtained through three centrifugation speeds.
Brazilian Journal of Veterinary Research and Animal Science 44:435-440.
Filardo, G., and E. Kon. 2015. PRP: product rich in placebo? Knee Surgery, Sports
Traumatology, Arthroscopy 23:1-2.
33

Gay, L.J., and B. Felding-Habermann. 2011. Contribution of platelets to tumour
metastasis. Nature Reviews. Cancer 11:123-134.
Girolamo, L., G. Filardo, M. Vigamo, and S. Zaffagnini. 2016. Meniscal repair:
enhancement of healing process. Pages 225-235 in C. Hulet, H. Pereira, G.
Peretti, M. Denti, editors. Surgery of the Meniscus. First edition. Springer,
Heidelberg, Berlim, Germany.
Hakimi, M., P. Jungbluth, M. Sager, M. Betsch, M. Herten, J. Becker, J. Windolf, and M.
Wild. 2010. Combined use of platelet-rich plasma and autologous bone grafts in
the treatment of long bone defects in mini-pigs. Injury 41:717-723.
Harvey, J.W. 2012. Veterinary hematology: a diagnostic guide and color atlas. First
edition. Saunders, St. Louis, Missouri, USA.
Hernandez-Fernandez, A., R. Velez, F. Soldado, J.C. Saenz-Rios, I. Barber, and M.
Aguirre-Canyadell. 2013. Effect of administration of platelet-rich plasma in early
phases of distraction osteogenesis: an experimental study in an ovine femur
model. Injury 44:901-907.
Holme, S. 1992. Effect of additive solutions on platelet biochemistry. Blood Cells
18:421-430.
Hottz, E.D., A.P. Monteiro, F.A. Bozza, and P.T. Bozza. 2015. Inflammasome in
platelets: allying coagulation and inflammation in infectious and sterile diseases?
Mediators of Inflammation 2015:435783.
Jee, C.H., N.Y. Eom, H.M. Jang, H.W. Jung, E.S. Choi, J.H. Won, I.H. Hong, B.T. Kang,
D.W. Jeong, and D.I. Jung. 2016. Effect of autologous platelet-rich plasma
application on cutaneous wound healing in dogs. Journal of Veterinary Science
17:79-87.
Jensen, T.B., O. Rahbek, S. Overgaard, and K. Soballe. 2004. Platelet rich plasma and
fresh frozen bone allograft as enhancement of implant fixation. An experimental
study in dogs. Journal of Orthopaedic Research 22:653-658.
Jensen, T.B., O. Rahbek, S. Overgaard, and K. Soballe. 2005. No effect of platelet-rich
plasma with frozen or processed bone allograft around noncemented implants.
International Orthopaedics 29:67-72.
Jiang, Z.Q., H.Y. Liu, L.P. Zhang, Z.Q. Wu, and D.Z. Shang. 2012. Repair of calvarial
defects in rabbits with platelet-rich plasma as the scaffold for carrying bone
marrow stromal cells. Oral Surgery, Oral Medicine, Oral Pathology and Oral
Radiology 113:327-333.

34

Karayannopoulou, M., D. Psalla, G. Kazakos, P. Loukopoulos, N. Giannakas, I. Savvas,
M. Kritsepi-Konstantinou, A. Chantes, and L.G. Papazoglou. 2015. Effect of
locally injected autologous platelet-rich plasma on second intention wound
healing of acute full-thickness skin defects in dogs. Veterinary and Comparative
Orthopaedics and Traumatology 28:172-178.
Kelton, J.G., P. Powers, J. Julian, V. Boland, C.J. Carter, M. Gent, and J. Hirsh. 1980.
Sex-related differences in platelet aggregation: influence of the hematocrit. Blood
56:38-41.
Kerr, B.A., R. Miocinovic, A.K. Smith, E.A. Klein, and T.V. Byzova. 2010. Comparison
of tumor and microenvironment secretomes in plasma and in platelets during
prostate cancer growth in a xenograft model. Neoplasia 12:388-396.
Kim, J.H., C. Park, and H.M. Park. 2009. Curative effect of autologous platelet-rich
plasma on a large cutaneous lesion in a dog. Veterinary Dermatology 20:123-126.
Koh, C.H., N. Bhoo-Pathy, K.L. Ng, R.S. Jabir, G.H. Tan, M.H. See, S. Jamaris, and
N.A. Taib. 2015. Utility of pre-treatment neutrophil-lymphocyte ratio and
platelet-lymphocyte ratio as prognostic factors in breast cancer. British Journal of
Cancer 113:150-158.
Koksch, M., F. Zeiger, K. Wittig, A. Siegemund, C.B. Reininger, D. Pfeiffer, and C.
Ruehlmann. 2001. Coagulation, fibrinolysis and platelet P-selectin expression in
peripheral vascular disease. European Journal of Vascular and Endovascular
Surgery 21:147-154.
Labelle, M., S. Begum, and R.O. Hynes. 2011. Direct signaling between platelets and
cancer cells induces an epithelial-mesenchymal-like transition and promotes
metastasis. Cancer Cell 20:576-590.
Lalko, C.C., E. Deppe, D. Ulatowski, A. Lutgen, A.P. Hart, E.A. Patton, D.P. Lunn, M.
Suresh, and B.J. Darien. 2003. Equine platelet CD62P (P-selectin) expression: a
phenotypic and morphologic study. Veterinary Immunology and
Immunopathology 91:119-134.
Lei, H., L. Gui, and R. Xiao. 2009. The effect of anticoagulants on the quality and
biological efficacy of platelet-rich plasma. Clinical Biochemistry 42:1452-1460.
Leytin, V., M. Mody, J.W. Semple, B. Garvey, and J. Freedman. 2000. Quantification of
platelet activation status by analyzing P-selectin expression. Biochemical and
Biophysical Research Communications 273:565-570.
Marx, R.E. 2001. Platelet-rich plasma (PRP): what is PRP and what is not PRP? Implant
Dentistry 10:225-228.
35

Mazzocca, A.D., M.B. McCarthy, J. Intravia, K. Beitzel, J. Apostolakos, M.P. Cote, J.
Bradley, and R.A. Arciero. 2013. An in vitro evaluation of the anti-inflammatory
effects of platelet-rich plasma, ketorolac, and methylprednisolone. Arthroscopy
29:675-683.
McCarrel, T.M., N.A. Mall, A.S. Lee, B.J. Cole, D.C. Butty, and L.A. Fortier. 2014.
Considerations for the use of platelet-rich plasma in orthopedics. Sports Medicine
44:1025-1036.
Meheux, C.J., P.C. McCulloch, D.M. Lintner, K.E. Varner, and J.D. Harris. 2016.
Efficacy of intra-articular platelet-rich plasma injections in knee osteoarthritis: a
systematic review. Arthroscopy 32:495-505.
Michelson, A.D., M.R. Barnard, H.B. Hechtman, H. MacGregor, R.J. Connolly, J.
Loscalzo, and C.R. Valeri. 1996. In vivo tracking of platelets: circulating
degranulated platelets rapidly lose surface P-selectin but continue to circulate and
function. Proceedings of the National Academy of Sciences of the United States
of America 93:11877-11882.
Monteiro, S.O., O.M. Lepage, and C.L. Theoret. 2009. Effects of platelet-rich plasma on
the repair of wounds on the distal aspect of the forelimb in horses. American
Journal of Veterinary Research 70:277-282.
Moojen, D.J., P.A. Everts, R.M. Schure, E.P. Overdevest, A. van Zundert, J.T. Knape,
R.M. Castelein, L.B. Creemers, and W.J. Dhert. 2008. Antimicrobial activity of
platelet-leukocyte gel against Staphylococcus aureus. Journal of Orthopaedic
Research 26:404-410.
Moritz, A., B.K. Walcheck, and D.J. Weiss. 2003. Flow cytometric detection of activated
platelets in the dog. Veterinary Clinical Pathology 32:6-12.
Moritz, A., B.K. Walcheck, and D.J. Weiss. 2005. Evaluation of flow cytometric and
automated methods for detection of activated platelets in dogs with inflammatory
disease. American Journal of Veterinary Research 66:325-329.
Murray, M.M., M. Palmer, E. Abreu, K.P. Spindler, D. Zurakowski, and B.C. Fleming.
2009. Platelet-rich plasma alone is not sufficient to enhance suture repair of the
ACL in skeletally immature animals: an in vivo study. Journal of Orthopaedic
Research 27:639-645.
Neufeld, M., U. Nowak-Gottl, and R. Junker. 1999. Citrate-theophylline-adeninedipyridamol buffer is preferable to citrate buffer as an anticoagulant for flow
cytometric measurement of platelet activation. Clinical Chemistry 45:2030-2033.
Nickels, R.M., U.T. Seyfert, E. Wenzel, M.D. Menger, and B. Vollmar. 2003. A simple
and reproducible method to reliably assess platelet activation. Thrombosis
Research 110:53-56.
36

Niemeyer, P., K. Fechner, S. Milz, W. Richter, N.P. Suedkamp, A.T. Mehlhorn, S.
Pearce, and P. Kasten. 2010. Comparison of mesenchymal stem cells from bone
marrow and adipose tissue for bone regeneration in a critical size defect of the
sheep tibia and the influence of platelet-rich plasma. Biomaterials 31:3572-3579.
Riboh, J.C., B.M. Saltzman, A.B. Yanke, L. Fortier, and B.J. Cole. 2016. Effect of
leukocyte concentration on the efficacy of platelet-rich plasma in the treatment of
knee osteoarthritis. The American Journal of Sports Medicine 44:792-800.
Rinnovati, R., N. Romagnoli, F. Gentilini, C. Lambertini, and A. Spadari. 2016. The
influence of environmental variables on platelet concentration in horse plateletrich plasma. Acta Veterinaria Scandinavica 58:45.
Sardari, K., M.R. Emami, H. Kazemi, A.R. Movasagi, A.A. Goli, A. Lotfi, and S.
Malekzadeh. 2011. Effects of platelet-rich plasma (PRP) on cutaneous
regeneration and wound healing in dogs treated with dexamethasone.
Comparative Clinical Pathology 20:155-162.
Segura, D., L. Monreal, S. Perez-Pujol, M. Pino, A. Ordinas, R. Brugues, J.G. White, and
G. Escolar. 2006. Assessment of platelet function in horses: ultrastructure, flow
cytometry, and perfusion techniques. Journal of Veterinary Internal Medicine
20:581-588.
Selvarajah, G.T., and J. Kirpensteijn. 2010. Prognostic and predictive biomarkers of
canine osteosarcoma. Veterinary Journal 185:28-35.
Senzel, L., D.V. Gnatenko, and W.F. Bahou. 2009. The platelet proteome. Current
Opinion in Hematology 16:329-333.
Silva, R.F., C.M.F. Rezende, F.O. Paes-Leme, and J.U. Carmona. 2011. Evaluación del
método del tubo para concentrar plaquetas caninas: estudio celular. Archivos de
Medicina Veterinaria 43:95-98.
Simsek, S.B., G.C. Keles, S. Baris, and B.O. Cetinkaya. 2012. Comparison of
mesenchymal stem cells and autogenous cortical bone graft in the treatment of
class II furcation defects in dogs. Clinical Oral Investigations 16:251-258.
Smith, S.A., M.A. McMichael, S. Gilor, A.J. Galligan, and C.M. Hoh. 2012. Correlation
of hematocrit, platelet concentration, and plasma coagulation factors with results
of thromboelastometry in canine whole blood samples. American Journal of
Veterinary Research 73:789-798.
Suharti, C., E.C. van Gorp, T.E. Setiati, W.M. Dolmans, R.J. Djokomoeljanto, C.E. Hack,
C.H. ten, and J.W. van der Meer. 2002. The role of cytokines in activation of
coagulation and fibrinolysis in dengue shock syndrome. Thrombosis and
Haemostasis 87:42-46.
37

Thiagarajan, P., and J.F. Tait. 1990. Binding of annexin V/placental anticoagulant protein
I to platelets. Evidence for phosphatidylserine exposure in the procoagulant
response of activated platelets. The Journal of Biological Chemistry 265:1742017423.
Tobita, M., C.A. Uysal, X. Guo, H. Hyakusoku, and H. Mizuno. 2013. Periodontal tissue
regeneration by combined implantation of adipose tissue-derived stem cells and
platelet-rich plasma in a canine model. Cytotherapy 15:1517-1526.
Torricelli, P., M. Fini, G. Filardo, M. Tschon, M. Pischedda, A. Pacorini, E. Kon, and R.
Giardino. 2011. Regenerative medicine for the treatment of musculoskeletal
overuse injuries in competition horses. International Orthopaedics 35:1569-1576.
Trichler, S.A., S.C. Bulla, J. Thomason, K.V. Lunsford, and C. Bulla. 2013. Ultra-pure
platelet isolation from canine whole blood. BMC Veterinary Research 9:144.
Weibrich, G., W.K. Kleis, W.E. Hitzler, and G. Hafner. 2005. Comparison of the platelet
concentrate collection system with the plasma-rich-in-growth-factors kit to
produce platelet-rich plasma: a technical report. The International Journal of Oral
& Maxillofacial Implants 20:118-123.
Werther, K., I.J. Christensen, and H.J. Nielsen. 2002. Determination of vascular
endothelial growth factor (VEGF) in circulating blood: significance of VEGF in
various leucocytes and platelets. Scandinavian Journal of Clinical and Laboratory
Investigation 62:343-350.
White, J.G. 2004. Electron microscopy methods for studying platelet structure and
function. Methods in Molecular Biology 272:47-63.
White, J.G., and G. Escolar. 2000. EDTA-induced changes in platelet structure and
function: adhesion and spreading. Platelets 11:56-61.
Wilkerson, M.J., and W. Shuman. 2001. Alterations in normal canine platelets during
storage in EDTA anticoagulated blood. Veterinary Clinical Pathology 30:107113.
Wills, T.B., K.J. Wardrop, and K.M. Meyers. 2006. Detection of activated platelets in
canine blood by use of flow cytometry. American Journal of Veterinary Research
67:56-63.
Yang, H., H.J. Ko, J.Y. Yang, J.J. Kim, S.U. Seo, S.G. Park, S.S. Choi, J.K. Seong, and
M.N. Kweon. 2013. Interleukin-1 promotes coagulation, which is necessary for
protective immunity in the lung against Streptococcus pneumoniae infection. The
Journal of Infectious Diseases 207:50-60.

38

Zhang, H., L. Gao, B. Zhang, L. Zhang, and C. Wang. 2016. Prognostic value of platelet
to lymphocyte ratio in non-small cell lung cancer: a systematic review and metaanalysis. Scientific Reports 6:22618.

39

